TruScreen Group Ltd. AI Stock Analysis
Want to see NZ:TRU full AI Analyst Report?
TruScreen Group Ltd. (TRU) AI Stock Analysis
TruScreen Group Ltd.
(NZX:TRU)
The score is primarily held back by weak financial performance—especially the sharp gross margin collapse, large ongoing losses, and persistent negative free cash flow that increases funding risk. Technicals also lean bearish with price below all major moving averages and negative MACD. Valuation provides limited support because the negative P/E reflects losses and dividend yield data is unavailable.
TruScreen Group Ltd. (TRU) vs. SPDR S&P 500 ETF (SPY)
- Market Cap
- NZD 4.94M
- Dividend Yield
- ―
- Average Volume (3M)
- 565.52K
- Price to Earnings (P/E)
- -2.6
- Beta (1Y)
- -0.11
- Revenue Growth
- 42.20%
- EPS Growth
- 23.68%
- Country
- NZ
- Employees
- 6
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Medical - Devices
TruScreen Group Ltd. Business Overview & Revenue Model
Company Description
TruScreen Group Limited, alongside its subsidiaries, focuses on the development, manufacturing, and global distribution of advanced systems for cancer detection. Their commercial reach extends across various international territories, including Mexic...
TruScreen Group Ltd. Financial Statement Overview
Summary
Despite a strong FY2026 revenue rebound (+58% vs FY2025), profitability and cash generation are very weak. FY2026 gross margin collapsed to ~1% and the company continues to post large operating/net losses (net margin about -93%), while operating cash flow and free cash flow remain consistently negative and deteriorated in FY2026—raising ongoing funding risk. The balance sheet is a relative bright spot with modest leverage (debt-to-equity ~0.08), but persistently negative ROE (roughly -87%) signals continuing capital pressure.
Income Statement
18Very NegativeBalance Sheet
57NeutralCash Flow
24Negative| Breakdown | TTM | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 2.43M | 2.43M | 1.71M | 2.60M | 1.66M | 1.68M |
| Gross Profit | 25.48K | 25.48K | 515.22K | 1.16M | 459.99K | 522.74K |
| EBITDA | -2.64M | -2.64M | -2.12M | -2.55M | -2.51M | -7.94M |
| Net Income | -2.25M | -2.25M | -2.24M | -2.05M | -2.40M | -7.89M |
Balance Sheet | ||||||
| Total Assets | 3.75M | 3.75M | 1.85M | 4.03M | 3.47M | 4.39M |
| Cash, Cash Equivalents and Short-Term Investments | 1.46M | 1.46M | 365.47K | 2.73M | 2.16M | 2.80M |
| Total Debt | 200.69K | 200.69K | 317.37K | 0 | 0 | 0 |
| Total Liabilities | 1.16M | 1.16M | 839.98K | 798.45K | 928.16K | 991.89K |
| Stockholders Equity | 2.59M | 2.59M | 1.01M | 3.23M | 2.54M | 3.40M |
Cash Flow | ||||||
| Free Cash Flow | -2.47M | -2.47M | -2.29M | -2.03M | -2.24M | -2.53M |
| Operating Cash Flow | -2.47M | -2.47M | -2.29M | -2.03M | -2.19M | -2.53M |
| Investing Cash Flow | 0 | 0 | 0 | 0 | -49.70K | -2,662 |
| Financing Cash Flow | 3.49M | 3.49M | -84.40K | 2.58M | 1.55M | 0 |
TruScreen Group Ltd. Peers Comparison
Overall Rating
NZ:FPH80Outperform
NZ:EBO56Neutral
NZ:AFT54Neutral
NZ:OCA54Neutral
NZ:TRU44Neutral
NZ:PEB42Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| 80Outperform | NZD 29.03B | 61.61 | 22.84% | 1.24% | 15.59% | 23.94% | |
| 56Neutral | NZD 4.54B | 16.71 | 7.99% | 5.69% | 16.36% | 5.52% | |
| 54Neutral | NZD 485.57M | 32.46 | 14.07% | 0.64% | 22.44% | 23.14% | |
| 54Neutral | NZD 449.02M | -63.44 | -0.57% | ― | 1.25% | -117.68% | |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| 44Neutral | NZD 8.38M | -2.58 | -75.57% | ― | 42.20% | 23.68% | |
| 42Neutral | NZD 341.52M | -6.66 | -190.54% | ― | -47.36% | -3.79% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| NZ:TRU | TruScreen Group Ltd. | 0.01 | -0.01 | -41.18% | |
| NZ:EBO | EBOS Group Limited | 21.65 | -5.75 | -20.98% | |
| NZ:FPH | Fisher & Paykel Healthcare Corporation Limited | 49.29 | 12.57 | 34.25% | |
| NZ:OCA | Oceania Healthcare Ltd. | 0.59 | -0.22 | -27.16% | |
| NZ:PEB | Pacific Edge Limited | 0.26 | 0.07 | 40.88% | |
| NZ:AFT | AFT Pharmaceuticals Ltd. | 4.59 | 0.93 | 25.38% |
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Oct 05, 2026
